12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Company News  |  Deals

Cellceutix, Pioneer Valley Life Sciences Institute deal

The parties partnered to research Cellceutix's Kevetrin to treat tumors associated with mitochondrial dysfunction due to aging. Kevetrin is a small molecule protein kinase B (PKB; PKBA; AKT; AKT1) inhibitor that also acts as...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >